Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment

Completed

• Conditions: Hearing Loss; Cancer

• Registration Number: NCT02381782
• Lead Sponsor: General Hospital Groeninge

Brief Summary

Over the last few years, there has been a considerable interest in the development of screening tools to assess the capability of elderly cancer patients to tolerate anti-cancer treatment. Therefore, the NCCN Guidelines in Senior Adult Oncology recommend an assessment of co-morbid conditions that are likely to interfere with cancer treatment and tolerability. As presbyacusis is common in an older population, elderly cancer patients are at high risk for social isolation and a reduced quality of life. Therefore, in this project the investigators aim to validatie uHear™ as a quick and reliable screening tool to screen for presbyacusisf in routine clinical oncology practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-12
• Study First Submitted: 2015-03-05
• Study First Submitted QC: 2015-03-05
• Study First Posted: 2015-03-06
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Status Verified: 2018-02
• Last Update Submitted: 2018-02-14
• Last Update Posted: 2018-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Patients should have reached the age of 70 or more at enrolment
• Histologically confirmed diagnosis of solid cancer or hematologic malignancy. All stages of cancer are eligible
• Patients should be fluent in Dutch or French
• Patients must receive their primary oncology care in the participating hospital
• Patients should be cognitively capable of performing the audiology assessment
• Patients should have signed informed consent

Exclusion Criteria

• Patients who do not match the above inclusion criteria
• Patients who are visiting the oncology clinic for a second opinion and do not wish to be treated in this clinic
• Patients presenting with clinically diagnosed Ménière's disease, retrocochlear hearing loss, autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural hearing loss
• Patients who already have a hearing aid or a previously diagnosed hearing loss

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Validation of uHear™ as a screening tool to detect hearing loss in elderly cancer patients	Baseline

Secondary Outcome Measures

Name	Time	Method
To compare uHear™ with the Whispered Voice Test	Baseline
To determine the prevalence of presbyacusis in an elderly cancer population	Baseline
To compare objective and subjective hearing screening measures	Baseline
To measure hearing impairment in G8 positive patients compared with G8 negative patients	Baseline
To evaluate the use of uHear™ as a measure to determine eligibility for cisplatin treatment in elderly cancer patients	Baseline

Trial Locations

Locations (1)

General Hospital Groeninge; 🇧🇪 Kortrijk, Belgium